Literature DB >> 32553430

A New Safety Approach Allowing Reversible Control of CAR T Cell Responses.

Amanda X Y Chen1, Imran G House1, Paul A Beavis2, Phillip K Darcy3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32553430      PMCID： PMC7335754          DOI： 10.1016/j.ymthe.2020.06.009

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Authors:  Victor D Fedorov; Maria Themeli; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-12-11       Impact factor: 17.956

2.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Authors:  Iulia Diaconu; Brandon Ballard; Ming Zhang; Yuhui Chen; John West; Gianpietro Dotti; Barbara Savoldo
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

Review 3.  The PI3K/AKT Pathway as a Target for Cancer Treatment.

Authors:  Ingrid A Mayer; Carlos L Arteaga
Journal:  Annu Rev Med       Date:  2015-10-14       Impact factor: 13.739

4.  A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.

Authors:  Reona Sakemura; Seitaro Terakura; Keisuke Watanabe; Jakrawadee Julamanee; Erina Takagi; Kotaro Miyao; Daisuke Koyama; Tatsunori Goto; Ryo Hanajiri; Tetsuya Nishida; Makoto Murata; Hitoshi Kiyoi
Journal:  Cancer Immunol Res       Date:  2016-06-21       Impact factor: 11.151

5.  Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.

Authors:  Takeya Sato; Anton Neschadim; Manfred Konrad; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

6.  Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.

Authors:  Wai-Hang Leung; Joel Gay; Unja Martin; Tracy E Garrett; Holly M Horton; Michael T Certo; Bruce R Blazar; Richard A Morgan; Philip D Gregory; Jordan Jarjour; Alexander Astrakhan
Journal:  JCI Insight       Date:  2019-04-30

7.  Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Authors:  Sarah K Tasian; Saad S Kenderian; Feng Shen; Marco Ruella; Olga Shestova; Miroslaw Kozlowski; Yong Li; April Schrank-Hacker; Jennifer J D Morrissette; Martin Carroll; Carl H June; Stephan A Grupp; Saar Gill
Journal:  Blood       Date:  2017-02-28       Impact factor: 22.113

8.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Authors:  Paulina J Paszkiewicz; Simon P Fräßle; Shivani Srivastava; Daniel Sommermeyer; Michael Hudecek; Ingo Drexler; Michel Sadelain; Lingfeng Liu; Michael C Jensen; Stanley R Riddell; Dirk H Busch
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

9.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

10.  Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Authors:  Chia-Yung Wu; Kole T Roybal; Elias M Puchner; James Onuffer; Wendell A Lim
Journal:  Science       Date:  2015-09-24       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.